BIOTIME, INC.

ALAMEDA, CA · Biotech · Public

Human embryonic stem cell-derived 3-D retinal tissue for subretinal transplantation to treat photoreceptor degeneration

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · biotime.space

Sector: Biotech
Headquarters: ALAMEDA, CA
Latest Form D: $3.5M, Mar 2014
Total capital: $27.1M

Federal grants: $2.2M; 3 awards · 2017–2019; Rank in peer group#492 of 514
Private capital raised: $24.9M; 7 Form D · last Mar 2014; 152 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 2; 17 pending · first 2015; Rank in peer group#142 of 514

Capital timeline

Latest events

Jul 2019Federal grantHealth and Human S · Phase II · Retinal tissue derived from human pluripotent stem cells for vision restoration$671K
Jun 2018Federal grantHealth and Human S · Phase II · Retinal tissue derived from human pluripotent stem cells for vision restoration$743K
Sep 2017Federal grantHealth and Human S · Phase II · Retinal tissue derived from human pluripotent stem cells for vision restoration$817K
Mar 2014Private capital raisedForm D · SEC · 7th filing$3.5M
Mar 2011Private capital raisedForm D · SEC · 6th filing$3.6M
Feb 2011Private capital raisedForm D · SEC · 5th filing$2.3M
May 2010Private capital raisedForm D · SEC · 4th filing$8M
May 2010Private capital raisedForm D · SEC · 3rd filing$61K
May 2009Private capital raisedForm D · SEC · 2nd filing$4M
Apr 2009Private capital raisedForm D · SEC · 1st filing$3.4M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median
Granted patents#142 · top 28%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Abraham E CohenDirectorNamed in SEC Form D filings
Alfred D KingsleyDirectorNamed in SEC Form D filings
Andrew C. von EschenbachDirectorNamed in SEC Form D filings
Arnold I BurnsDirectorNamed in SEC Form D filings
Franklin M. BergerDirectorNamed in SEC Form D filings
Gregg ValetaDirectorNamed in SEC Form D filings

Show all 20 people

Hal SternbergExecutive Officer, DirectorNamed in SEC Form D filings
Harold WaitzExecutive Officer, DirectorNamed in SEC Form D filings
Henry L. NordhoffDirectorNamed in SEC Form D filings
Judith SegallExecutive Officer, DirectorNamed in SEC Form D filings
Michael D WestExecutive Officer, DirectorNamed in SEC Form D filings
Neal C BradsherDirectorNamed in SEC Form D filings
Pedro D LichtingerDirectorNamed in SEC Form D filings
Robert N ButlerDirectorNamed in SEC Form D filings
Robert W PeabodyExecutive OfficerNamed in SEC Form D filings
Stephen C. FarrellDirectorNamed in SEC Form D filings
Steven A SeinbergExecutive OfficerNamed in SEC Form D filings
Valeta A GreggDirectorNamed in SEC Form D filings
Walter W FunkExecutive OfficerNamed in SEC Form D filings
William P. TewExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 19

Jul 23, 2020PendingImplants, Methods For Making Implants And Methods Of Treating Lipoatrophy Defects TherewithUSPTOApplication 16708725
Nov 27, 2018GrantedThiolated Hyaluronan-based Hydrogels Cross-linked Using Oxidized GlutathioneUSPTOUS 10,137,199
Nov 3, 2015GrantedMethods and Compositions for Targeting Progenitor Cell LinesUSPTOUS 9,175,263

Show all 19 patent records

Implants, Methods For Making Implants And Methods Of Treating Lipoatrophy Defects TherewithJul 23, 2020 · Application 16708725Pending
Thiolated Hyaluronan-based Hydrogels Cross-linked Using Oxidized GlutathioneNov 27, 2018 · US 10,137,199Granted
Methods and Compositions for Targeting Progenitor Cell LinesNov 3, 2015 · US 9,175,263Granted
Improved Methods For Detecting And Modulating The Embryonic-fetal Transition In Mammalian SpeciesApplication PCTUS2017036452Pending
Pluripotent Stem Cell-derived 3D Retinal Tissue And Uses ThereofApplication PCTUS2017026016Pending
Methods For The Re-derivation Of Diverse Pluripotent Stem Cell-derive Brown Fat CellsApplication PCTUS2016065366Pending
Methods for Generating Pluripotent Stem Cell-Derived Brown Fat CellsApplication 62020343Pending
Compositions And Methods For Induced Tissue Regeneration In Mammalian SpeciesApplication PCTUS2014040601Pending
Methods for Generating Pluripotent Stem Cell-Derived Brown Fat CellsApplication 61908621Pending
Compositions and Methods for Induced Tissue Regeneration in Mammalian SpeciesApplication 61831421Pending
Compositions And Methods Relating To Clonal Progenitor Cell LinesApplication PCTUS2012054525Pending
Novel Methods And Formulations For Orthopedic Cell TherapyApplication PCTUS2012046564Pending
Methods Of Modifying Transcriptional Regulatory Networks In Stem CellsApplication PCTUS2011057387Pending
Improved Methods Of Screening Embryonic Progenitor Cell LinesApplication PCTUS2011037969Pending
Methods For Telomere Length And Genomic Dna Quality Control Analysis In Pluripotent Stem CellsApplication PCTUS2011025316Pending
Methods And Compositions For In Vitro And In Vivo ChondrogenesisApplication PCTUS2010042369Pending
Methods And Devices For Thawing And/or Imaging Frozen Biological Samples.Application PCTUS2007007915Pending
Compositions And Methods For Restoring Or Preventing Loss Of Vision Caused By Disease Or Traumatic InjuryApplication PCTUS2018044720Pending
Implants, Methods For Making Implants And Methods Of Treating Lipoatrophy Defects TherewithApplication PCTUS2018037174Pending

GlycosBio Inc.Similar federal contract value in Biotech · null in contracts
ARONORA INCSimilar federal contract value in Biotech · null in contracts
MABVAX THERAPEUTICS HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
HELIUS MEDICAL TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
GID BIO, Inc.Similar federal contract value in Biotech · null in contracts
AXILEA LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.